• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

十年动脉粥样硬化性心血管疾病风险变化率及其对一级预防的影响。

Rate of Change in 10-Year Atherosclerotic Cardiovascular Disease Risk and Its Implications for Primary Prevention.

机构信息

Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Gyeonggi, South Korea (I.-C.H., H.-M.C., Y.E.Y., G.-Y.C.).

Department of Internal Medicine, Seoul National University College of Medicine, South Korea (I.-C.H., H.-M.C., Y.E.Y., G.-Y.C.).

出版信息

Hypertension. 2023 Aug;80(8):1697-1706. doi: 10.1161/HYPERTENSIONAHA.122.20678. Epub 2023 May 31.

DOI:10.1161/HYPERTENSIONAHA.122.20678
PMID:37470768
Abstract

BACKGROUND

Contemporary cardiovascular primary prevention is based on the assessment of the 10-year risk of atherosclerotic cardiovascular disease (ASCVD). However, the clinical implications of temporal change in the 10-year ASCVD risk estimate (∆10-year ASCVD risk/year) are unknown.

METHODS

A total of 211 077 participants without established ASCVD and with repetitive 10-year ASCVD risk assessment at an interval of 4 to 5 years were selected from the Korean National Health Insurance Service data. The primary end point was a composite of myocardial infarction, stroke, coronary revascularization, and all-cause death.

RESULTS

ASCVD event rates were proportional to the ∆10-year ASCVD risk/year regardless of the baseline 10-year ASCVD risk. Adjusted hazard ratio for ASCVD events per 1% increase in ∆10-year ASCVD risk/year was 1.53 (95% CI, 1.44-1.63), 1.24 (95% CI, 1.15-1.32), 1.18 (95% CI, 1.13-1.23), and 1.05 (95% CI, 1.00-1.10) in those with a baseline 10-year ASCVD risk of <5%, 5% to 7.5%, 7.5% to 20%, and ≥20%, respectively. Appropriate control of risk factors, including low-density lipoprotein cholesterol, blood pressure, body mass index, exercise habits, and smoking status, was associated with lower ASCVD event rates, whereas failure to control these risk factors resulted in higher ASCVD event rates.

CONCLUSIONS

The temporal change in 10-year ASCVD risk over a period of 4 to 5 years reflects success or failure in controlling major cardiovascular risk factors and indicates the risk of future ASCVD events. The ∆10-year ASCVD risk/year can be used as an indicator of primary prevention and guide the application of preventive measures.

摘要

背景

当代心血管一级预防基于评估发生动脉粥样硬化性心血管疾病(ASCVD)的 10 年风险。然而,10 年 ASCVD 风险估计值(∆10 年 ASCVD 风险/年)的时间变化的临床意义尚不清楚。

方法

从韩国国家健康保险服务数据中选择了 211077 名没有确诊 ASCVD 且重复进行 4 至 5 年间隔的 10 年 ASCVD 风险评估的参与者。主要终点是心肌梗死、卒中和冠状动脉血运重建以及全因死亡的复合事件。

结果

无论基线 10 年 ASCVD 风险如何,ASCVD 事件发生率均与 ∆10 年 ASCVD 风险/年成正比。每增加 1% ∆10 年 ASCVD 风险/年,ASCVD 事件的调整后风险比为 1.53(95%CI,1.44-1.63)、1.24(95%CI,1.15-1.32)、1.18(95%CI,1.13-1.23)和 1.05(95%CI,1.00-1.10),基线 10 年 ASCVD 风险<5%、5%至 7.5%、7.5%至 20%和≥20%的参与者。包括低密度脂蛋白胆固醇、血压、体重指数、运动习惯和吸烟状况在内的危险因素的适当控制与较低的 ASCVD 事件发生率相关,而未能控制这些危险因素则导致更高的 ASCVD 事件发生率。

结论

在 4 至 5 年期间,10 年 ASCVD 风险的时间变化反映了控制主要心血管危险因素的成功或失败情况,并预示着未来发生 ASCVD 事件的风险。∆10 年 ASCVD 风险/年可作为一级预防的指标,并指导预防措施的应用。

相似文献

1
Rate of Change in 10-Year Atherosclerotic Cardiovascular Disease Risk and Its Implications for Primary Prevention.十年动脉粥样硬化性心血管疾病风险变化率及其对一级预防的影响。
Hypertension. 2023 Aug;80(8):1697-1706. doi: 10.1161/HYPERTENSIONAHA.122.20678. Epub 2023 May 31.
2
Is carotid artery evaluation necessary for primary prevention in asymptomatic high-risk patients without atherosclerotic cardiovascular disease?对于无动脉粥样硬化性心血管疾病的无症状高危患者,颈动脉评估对一级预防是否必要?
Clin Interv Aging. 2015 Jul 7;10:1111-9. doi: 10.2147/CIA.S85216. eCollection 2015.
3
Impact of outcome definitions on cardiovascular risk prediction in a contemporary primary prevention population.对当代一级预防人群中,不同终点定义对心血管风险预测的影响。
Eur Heart J Qual Care Clin Outcomes. 2023 Jun 21;9(4):427-434. doi: 10.1093/ehjqcco/qcac044.
4
High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study.高敏 C 反应蛋白与致动脉粥样硬化脂质指标不相符与一级预防中动脉粥样硬化性心血管疾病的发生:ARIC 研究。
J Am Heart Assoc. 2020 Feb 4;9(3):e013600. doi: 10.1161/JAHA.119.013600. Epub 2020 Jan 30.
5
Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.在现行胆固醇指南的动脉粥样硬化性心血管疾病框架中,高敏肌钙蛋白检测的临床应用。
JAMA Cardiol. 2020 Nov 1;5(11):1255-1262. doi: 10.1001/jamacardio.2020.2981.
6
Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and Older.他汀类药物使用与美国 75 岁及以上退伍军人全因和心血管死亡率的关系。
JAMA. 2020 Jul 7;324(1):68-78. doi: 10.1001/jama.2020.7848.
7
Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study.韩国的动脉粥样硬化性心血管疾病及其危险因素的患病率和发病率:一项全国性基于人群的研究。
BMC Public Health. 2019 Aug 14;19(1):1112. doi: 10.1186/s12889-019-7439-0.
8
Prediction of the 10-year risk of atherosclerotic cardiovascular disease in the Korean population.预测韩国人群的动脉粥样硬化性心血管疾病 10 年风险。
Epidemiol Health. 2023;45:e2023052. doi: 10.4178/epih.e2023052. Epub 2023 May 12.
9
Prevalence of atherosclerotic cardiovascular disease and subsequent major adverse cardiovascular events in Alberta, Canada: A real-world evidence study.加拿大艾伯塔省动脉粥样硬化性心血管疾病的流行情况及随后发生的主要不良心血管事件:一项真实世界证据研究。
Clin Cardiol. 2021 Nov;44(11):1613-1620. doi: 10.1002/clc.23732. Epub 2021 Sep 29.
10
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.评估已患有心血管疾病患者的复发性动脉粥样硬化性心血管事件风险:更新的 SMART2 算法。
Eur Heart J. 2022 May 7;43(18):1715-1727. doi: 10.1093/eurheartj/ehac056.

引用本文的文献

1
Combination of Polydatin and Hawthorn Leave Flavonoids Ameliorate Atherosclerotic Plaque Vulnerability in ApoE Mice by Regulating Ferroptosis via the Nrf2/HO-1/GPX4 Axis.虎杖苷与山楂叶黄酮联合通过Nrf2/HO-1/GPX4轴调控铁死亡改善ApoE小鼠动脉粥样硬化斑块易损性
J Inflamm Res. 2025 Sep 2;18:12105-12121. doi: 10.2147/JIR.S530995. eCollection 2025.
2
Role of naringin in the treatment of atherosclerosis.柚皮苷在动脉粥样硬化治疗中的作用。
Front Pharmacol. 2024 Sep 6;15:1451445. doi: 10.3389/fphar.2024.1451445. eCollection 2024.
3
Sarcopenia as a risk factor for hypertension.
肌肉减少症作为高血压的一个风险因素。
Hypertens Res. 2024 Dec;47(12):3363-3366. doi: 10.1038/s41440-024-01898-y. Epub 2024 Sep 19.
4
Changes in Risk Factor Status and Risk of Future ASCVD Events in Primary Prevention.一级预防中危险因素状态的变化与未来动脉粥样硬化性心血管疾病(ASCVD)事件的风险
Korean Circ J. 2024 Jun;54(6):354-356. doi: 10.4070/kcj.2024.0020. Epub 2024 Apr 11.
5
Age-dependent implications of left ventricular hypertrophy regression in patients with hypertension.高血压患者左心室肥厚消退的年龄依赖性影响
Hypertens Res. 2024 May;47(5):1144-1156. doi: 10.1038/s41440-023-01571-w. Epub 2024 Jan 18.
6
Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis.芒果苷与靶向自噬的T0901317联合使用可促进动脉粥样硬化中巨噬细胞泡沫细胞的胆固醇流出。
Chin Med. 2024 Jan 5;19(1):5. doi: 10.1186/s13020-023-00876-9.